New Treatment Potential for Depressed, Suicidal Patients With Ketamine, Says Expert
There’s new hope for depressed and suicidal patients with ketamine therapy, says University of Alabama doctor Richard C. Shelton.
There’s new hope for depressed and suicidal patients with ketamine therapy, says University of Alabama doctor Richard C. Shelton.
This week in psychedelic business news: LSD for pain, DMT and organ transplants, Champignon Brands is now Braxia Scientific Corp, and more.
New treatment interventions approved by NIMH for use with high-suicide risks include two novel ketamine therapies.
A nasal spray of ketamine proved to be highly effective at treating a type of migraine called refractory migraines, according to a new study.
Psychedelic life sciences company MindMed is exploring LSD as a means of pain management.
New Leaf Canada has received permission from Health Canada to build a first-of-its-kind laboratory to produce and study psilocybin and psilocin.
A new psychedelic VR experience is coming thanks to a partnership between Lobe Sciences and Virtual Psychedelics.
The first phase-3 trial of its kind investigating MDMA for PTSD is showing promising results.
Researchers have identified a psychedelic with no hallucinogenic characteristics using a new sensor.
Actor and former NFL safety Kerry Rhodes says the psychedelic compound ayahuasca has helped him recover from brain injuries.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.